Eli Lilly and Company & Sanofi

Eli Lilly and Company: Eli Lilly has a strategic collaboration with Scribe, which may benefit from Scribe's successful IPO and pipeline progress.

Sanofi: Sanofi participated in a concurrent private placement, purchasing 500,000 shares for $7.5 million, and has a prior $1.5 billion research collaboration with Scribe. This deepens Sanofi's strategic involvement in gene editing and cardiovascular therapies.

Eli Lilly and Company: Eli Lilly competes with Novo Nordisk in the obesity treatment market, but this launch is focused on diabetes.

Sanofi: Sanofi's Lantus faces new competition from Awiqli, which offers less frequent dosing and lower cost per unit.

Eli Lilly and Company: Eli Lilly is mentioned as the former employer of Alpheus Bingham, who helped build an internal prediction market.

Sanofi: Sanofi is one of the companies whose drug approvals are being bet on, but is not directly involved.

Sanofi: Sanofi is a major insulin maker that has moved to cut the cost of insulin and offers a savings program for people without health insurance.